Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3569181 | 0.94 | PTPRB (0.71) | PTPRBCCR3 | |
| SCHEMBL27883944 | 0.94 | PTPRB (0.71) | PTPRBCCR3 | |
| SCHEMBL468090 | 0.94 | PTPRB (0.71) | PTPRBCCR3 | |
| SCHEMBL468091 | 0.94 | PTPRB (0.71) | PTPRBCCR3 | |
| SCHEMBL19502576 | 0.92 | PTPRB (0.72) | PTPRB | |
| SCHEMBL14314329 | 0.92 | PTPRB (0.72) | PTPRB | |
| SCHEMBL12084515 | 0.92 | PTPRB (0.72) | PTPRB | |
| SCHEMBL3574856 | 0.89 | PTPRB (0.74) | PTPRBCCR3 | |
| SCHEMBL684240 | 0.89 | PTPRB (0.74) | PTPRBCCR3 | |
| SCHEMBL12944445 | 0.89 | PTPRB (0.55) | PTPRBCCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4101297-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Pharmaceuticals, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220117946-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2022-04-21 | — | — | US | disclosed |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2020-11-19 | — | — | US | disclosed |
| US-20200253936-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2020-08-13 | — | — | US | disclosed |
| EP-3607821-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Therapeutics, Inc. (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10463650-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | Aerpio Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-2967066-B1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | AERPIO THERAPEUTICS INC (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20180251457-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-09-06 | — | — | US | disclosed |
| US-20180237429-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-08-23 | — | — | US | disclosed |
| US-20180237430-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-08-23 | — | — | US | disclosed |
| US-8946232-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8895563-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140275103-A1 | Compositions, formulations and methods for treating ocular diseases | AERPIO THERAPEUTICS INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140221666-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130324558-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20130096140-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-8258311-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20100069448-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2010-03-18 | — | — | US | disclosed |
| US-20100016336-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2010-01-21 | — | — | US | disclosed |
| US-7622593-B2 | 4-{2-[2-(tert-Butoxycarbonyl)-3-phenylpropanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | THE PROCTER & GAMBLE COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096140-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885CCR3 3721/4885 |
| US-20100016336-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885CCR3 3721/4885 |
| US-20220117946-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885CCR3 3721/4885 |
| US-10463650-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885CCR3 3721/4885 |
| US-20200253936-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885CCR3 3721/4885 |
| US-20140275103-A1 | Compositions, formulations and methods for treating ocular diseases | TIE1, TEK, KDR | PTPRB 609/4885CCR3 3589/4885 |
| US-20180237429-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885CCR3 3589/4885 |
| US-20180237430-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885CCR3 3589/4885 |
| US-20180251457-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885CCR3 3589/4885 |
| US-20100069448-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885CCR3 3721/4885 |
| US-20140221666-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885CCR3 3721/4885 |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885CCR3 3589/4885 |
| US-20130324558-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885CCR3 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.